cagrilintide/semaglutide vs HRS-7535

NCT05394519 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.

NCT06904105 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial (n=556). The primary endpoint, percent weight change at week 44, was met: participants lost 9.5% (120 mg) and 10.9% (180 mg) of body weight versus 2.5% with placebo.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT05394519 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.

NCT06672172 · Phase 3 · completed

This is a well-designed randomized, double-blind, placebo-controlled trial with a recognized clinical measure (HbA1c change) as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.